Shanghai Creation Investment (SCI), founded in 2006, is an international venture capital firm and investment bank focused on high tech and healthcare technology. Based in Shanghai, SCI has investments in Asia, the Middle East, and the United States.
SCI devoted years of efforts forming a complete eco-system for value creation for investors. Over the last 10 years, SCI has successfully assisted more than 50 US/Israel/Chinese firms in private placement, M&A, or public offering. Raised a total amount of more than S1.25$ billion in private placement. SCI‘s investment portfolio includes 11 international star-ups and 15 Chinese companies by mid of 2017 in healthcare and hi-tech. 5 of the 25 investments are listed in the public stock market in China and USA by today.
In the healthcare domain, SCI works with a large network of more than 100 hospitals and 300+ doctors in China, the Middle East, and North America, in due diligence and clinical trials for SCI’s portfolio companies. The network also contributes significant help to industry researches.
SCI was awarded “Top 10 Venture Capital Firms of the Year 2016” by Private Equity Association of Shanghai, which is the largest and most important VC organization in Shanghai , with more than 330 major PE/VC firms as members.